Skip to main content

Table 4 Factors affecting the yield of re-biopsy by EBUS-GS (N = 44)

From: Re-biopsy by endobronchial ultrasound procedures for mutation analysis of non-small cell lung cancer after EGFR tyrosine kinase inhibitor treatment

 

Success (n = 33)

Failure (n = 11)

Univariate

Multivariate

p value

p value

Odds ratio

Age (years)

  

0.722

 ≤70

23 (52.3)

7 (15.9)

   

 >70

10 (22.7)

4 (9.1)

   

Gender

  

0.282

 Male

13 (29.5)

2 (4.5)

   

 Female

20 (45.5)

9 (20.5)

   

ECOG PS

  

1.0

 0/1

31 (70.5)

10 (22.7)

   

 2/3/4

2 (4.5)

1 (2.3)

   

Size (mm)

  

0.139

 ≤30

7 (15.9)

5 (11.4)

   

 >30

26 (59.1)

6 (13.6)

   

Location

  

0.043

0.034

15.7

 Central parenchymal

32 (72.7)

8 (18.2)

   

 Peripheral parenchymal

1 (2.3)

3 (6.8)

   

Bronchus sign

  

0.027

0.239

 Positive

31 (70.5)

7 (15.9)

   

 Negative

2 (4.5)

4 (9.1)

   

Biopsied pulmonary lesion

  

0.154

 Primary malignant

30 (68.2)

8 (18.2)

   

 Metastatic

3 (6.8)

3 (6.8)

   

Chest radiograph

  

0.090

0.080

 Visible

31 (70.5)

8 (18.2)

   

 Invisible

2 (4.5)

3 (6.8)

   

EBUS

  

0.016

0.012

10.0

 Within

30 (68.2)

6 (13.6)

   

 Adjacent to/invisible

3 (6.8)

5 (11.4)

   
  1. Data are presented as number (%)
  2. EBUS-GS endobronchial ultrasound with a guide sheath, ECOG PS Eastern Cooperative Group performance status, EBUS Endobronchial ultrasound